Large retrospective studies have demonstrated that concurrent anti-EGFR therapy provides similar survival benefits with fewer toxicities, such as hematologic toxicities and gastrointestinal reactions, than concurrent chemotherapy for NPC patients (9). Here, EGFR is linked to nasopharyngeal carcinoma.